louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00284895: The Effect of Obesity on Lung Functioning
Official title: The Effect of Medical and Surgical Weight Loss on Pulmonary Physiology and Airway
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Asthma
Keywords: Obesity
Bariatric Surgery
Weight Loss Surgery
Asthma
Lead sponsor: National Jewish Health
Sponsor class: OTHER
First posted: 2006-02-01
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: This research study is looking at the effects of weight loss, due to surgery or structured weight-loss program on lung function, inflammation in your body and lungs, asthma and asthma symptoms. This study is important because we will be better able to understand the effect of weight on lung functioning and asthma. Approximately 20 research subjects will be enrolling in this study at National Jewish.

Adults with asthma who has elected to undergo weight-reduction surgery may qualify for the participation. Involvement will last about 1 year.


Eligibility criteria: Inclusion Criteria:

* Adults (≥18yr) who report a physician's diagnosis of asthma and have taken any asthma medication within the last 2 weeks.
* Obesity (Body Mass Index (BMI) ≥40, or ≥35 with comorbidities, as per published guidelines for qualification for bariatric surgery).
* Planned weight-loss surgery or structured weight-loss plan.

Exclusion Criteria:

* Tobacco use within one month.
* Qualifying lung-functioning.
* Qualifying oxygen saturation levels.
* Use of systemic corticosteroids (Prednisone) within one month.
* Presence of another chronic lung disease besides asthma (COPD, bronchiectasis, ILD, sarcoidosis, etc).
* Presence of another chronic systemic inflammatory disease (rheumatoid arthritis or other connective-tissue disease, chronic infection such as osteomyelitis, inflammatory bowel disease, chronic active hepatitis, etc). Subjects with osteoarthritis, stable coronary artery disease, hypertension, or diabetes mellitus will not be excluded.
* Presence of malignant neoplasm within the last 3 years (with the exception of non-melanoma skin cancer).
* Clinically significant left or right ventricular dysfunction.
* Severe pulmonary hypertension (high blood pressure).
* Untreated obstructive sleep apnea:
* Subjects with a current diagnosis of sleep apnea not being treated with CPAP or BiPAP will be excluded.
* Subjects with a current diagnosis of sleep apnea being treated adequately (as determined by the investigators) will be included.
* Prader-Willi syndrome
* A known endocrinopathy causing obesity (e.g., Cushing's Syndrome).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: National Jewish Medical and Research Center
state: Colorado
Study officials:
affiliation: National Jewish Medical and Research Center faculty
name: David Beuther, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00694395: A Qualitative Study of Delays in Hospital Admission in Patient With Acute Stroke
Official title: Decision Making Process in Patients With Symptoms of Acute Ischemic Stroke Why do They Delay in Seeking Medical Help? A Qualitative Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Ischemic Stroke
Keywords: Qualitative study
stroke
20 patients, Family or caregivers
acute ischemic stroke
delayed to receive thrombolytic therapy.
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
Collaborators: name: Fu Jen Catholic University
First posted: 2008-06-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 20 patients admitted to hospital due to acute ischemic stroke and were delayed to receive thrombolytic therapy. Family or caregivers who had involved in the process of decision making were also invited to the interview.

Brief summary: To identify the circumstance during decision making processes to seek medical help in patients with symptoms of acute ischemic stroke.


Eligibility criteria: Inclusion Criteria:

* patients with confirmed acute ischemic stroke by brain image and were able to communicate in Mandarin or Taiwanese.

Exclusion Criteria:

* patients who had cerebral hemorrhage, aphasia, cognitive dysfunction or severe stroke with unstable vital sign.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00498095: A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies
Official title: Experience of C4d Staining in Renal Allograft Biopsies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Transplantation
Graft Rejection
Keywords: Delayed renal graft function
Acute renal allograft dysfunction
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
First posted: 2007-07-09
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All renal allograft biopsies performed in Princess Margaret Hospital from 1st April 2002 to 31st March 2006 on Chinese patients who were ≥ 18 years old were retrospectively reviewed. Renal transplantations were either cadaveric or living-donor related performed in Hong Kong or Mainland China. All recipients' sera produced negative cross-match tests with donor lymphocytes before transplantation and were ABO compatible. Finally, 52 renal biopsies were included. 38 (73.1%) of them were performed for unexplained acute renal deterioration whilst the rest were done for delayed graft function.

Brief summary: Patients who had received kidney transplantation may suffer from rejection. Recently, positive staining for C4d in kidney biopsies of malfunctioning transplant kidney is increasingly recognized as an important prognostic indicator of poorer long-term kidney outcome. Data is, however, lacking in Hong Kong.


Eligibility criteria: Inclusion Criteria:

* All renal allograft biopsies performed in Princess Margaret Hospital (PMH) during the period 1st April 2003 to 31st August 2005 for unexplained acute renal dysfunction (Creatinine rise from baseline by ≥ 20%) or delayed graft function in the immediate post-transplantation period were included in the study. Both cadaveric and living-donor transplant allografts were included.

Exclusion Criteria:

* patients who were \< 18 years' old at the time of renal biopsy or whose records were so incomplete that preclude meaningful analysis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Princess Margaret Hospital
Study officials:
affiliation: Department of Medicine & Geriatrics, ICU, Caritas Medical Centre
name: Sze Kit Yuen, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01866995: Efficacy Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)
Official title: Phase 3 Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)Caused By Decrease Of Sexual Activity In Men.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Congestive Processes Of The Pelvic Organs (Prostatostasis)
Erectile Dysfunction
Sexual Function
Keywords: Ginseng
Prostatostasis
Erectile Dysfunction
Lead sponsor: The Clinic of Men's Health and Couple Longevity, Russia
Sponsor class: OTHER
First posted: 2013-06-03
Enrollment: 50
Sex: MALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy of Phytotherapy "Raylis" (Ginseng Root Powder 50 mg, False Ginseng Root Powder 50 mg, Codonopsis Root Powder 50 mg, Astragalus Membranaceus Root Powder 50 mg, Epimedium Alpinum Herbal Extract 100 mg) In Congestive Processes Of The Pelvic Organs (Prostatostasis) In Congestive Processes Of The Pelvic Organs (Prostatostasis)


Eligibility criteria: Inclusion Criteria:

* Age 20-60 years
* Symptoms of prostatostasis lasting for at least 3 months during the past 6 months:
* Pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s, average urinary flow rate of less than 12 ml / sec)
* TRUS Prostate volume more than 22 ml at TRUS
* TRUS picture of Prostatostasis
* I-PSS 7-20
* IIEF-5) - 12-21

Exclusion Criteria:

* Contraindications and limitations to use of the drug Raylis listed in the instructions for medical use \*
* Diabetes mellitus (type 1 and type 2, decompensation)
* Neurogenic disorders (acute cerebral circulatory disorders, Alzheimer's disease, spinal cord injury)
* A history of pelvic trauma
* Patients who had undergone radical prostatectomy and other surgical interventions on the pelvic organs
* Concomitant use of supplements to improve the erectile function, use of the anti-androgens, anti-depressants, finasteride.
* Diagnosed BPH
* Current participation in a clinical trial and / or study medication for 30 days prior to inclusion
* Any form of substance abuse, mental disorder or condition which, in the opinion of the investigator, may complicate communication with the researcher.
* The inability or unwillingness to comply with the scheme of visits according to protocol.

Primary outcomes:
measure: TRUS prostate
timeFrame: 3 months
Secondary outcomes:
measure: Uroflowmetry
timeFrame: 3 months
Other outcomes:
measure: IPSS
timeFrame: 3 months
Locations:
city: Moscow
country: Russian Federation
facility: Clinic Of Men's Health and Couple Longevity
Study officials:
affiliation: Clinic of Men's Health and Couple Longevity, str Zoologicheskaya, 2-7 Moscow Russia
name: Svetlana Kalinchenko, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02425995: Interest of Additional Arthroscopic Portals in Diagnosis of Hidden Lesions of the Medial Meniscus in Pediatrics Knees With ACL Deficiency
Official title: Prevalence and Diagnosis of Hidden Lesions of the Posterior Horn of the Medial Meniscus in Pediatric Anterior Cruciate Ligament (ACL) Lesions : Interest of Arthroscopic Intercondylar and Posteromedial Portals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Knee Instability
Keywords: ACL
Hidden lesions of the medial meniscus
Chronic knee instability
Intercondylar and posteromedial arthroscopy
Arthroscopic Posteromedial and Intercondylar portal
Diagnosis capacity of hidden lesions of the medial meniscus
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2015-04-24
Enrollment: 43
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Peroperatively observative study in pediatric orthopedic center in Lyon, France.

50 pediatric patients included in this study, to improve the diagnosis of hidden lesions of the medial meniscus associated with lesions of the anterior cruciate ligament.

All the patients need a reconstruction of the ACL because of chronic knee instability.

All the patients underwent a multi portal arthroscopy during the ACL reconstruction : anteromedial and anterolateral and after intercondylar and posteromedial.

The study consists in a peroperatively arthroscopic look, in order to diagnose lesions of the posterior horn of the medial meniscus which could be missed in MRI and anteromedial and anterolateral arthroscopy.

Statistics of this lesions are used to study prevalence and diagnosis capacity of this procedures.

First, the surgeon did a classic knee arthroscopy. Secondarily, he did an intercondylar portal and after a posteromedial portal.


Eligibility criteria: Inclusion Criteria:

- Chronic knee instability with indicated surgery reconstruction

Exclusion Criteria:

* Pregnancy
* No preoperatively knee MRI
* Posteromedial or Intercondylar Portal Failure
* Social security system membership failure
* Refusal of consent of child or parents

Primary outcomes:
measure: Number of hidden lesions diagnosed in Arthroscopic Posteromedial Portal and not seen in classic arthroscopic portals and Intercondylar Portal.
timeFrame: Day 1 (during surgery)
Secondary outcomes:
measure: Number of hidden lesions diagnosed during the arthroscopic procedure and not seen in preoperatively MRI.
timeFrame: Day 1 (during surgery)
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
affiliation: Service de Chirurgie Orthopédique Pédiatrique - Hôpital Femme Mère Enfant - 59, Bd Pinel 69677 BRON CEDEX
name: Franck CHOTEL, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00291395: PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Headache
Migraine
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2006-02-14
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Before , during and after intravenous administration of PGI2 we score/measure headache, rCBF, blood flow in middle cerebral artery and diameter of superficial temporal artery/radial artery and correlate that to known patophysiology of headache to see if PGI2 is involved in headache pathophysiology.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers,

Exclusion Criteria:

* Primary headache,
* headache on the day of investigation,
* Hypertension,
* hypotension,
* pregnant/nursing
* Daily intake of medication (except oral contraceptives)
* Cardiovascular or CNS disease
* Drug/Alcohol abuse
* Psychiatric disease

Primary outcomes:
measure: Headache
Secondary outcomes:
measure: rCBF, blood flow, diameter of STA/RA, HR, BP
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
Study officials:
affiliation: Danish Headache Center
name: Troels Wienecke, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04772495: miRNA Biomarkers in Multiple Sclerosis
Official title: The Potential Candidate miRNA Biomarkers in Multiple Sclerosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
miRNA
Epigenetic
Biomarker
Keywords: Multiple sclerosis
miRNA biomarkers
peripheral blood molecular diagnostics
Lead sponsor: University of Gaziantep
Sponsor class: OTHER
First posted: 2021-02-26
Enrollment: 69
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients who had been diagnosed with Multiple sclerosis and healthy male and female

Brief summary: Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic inflammatory disease of the central nervous system (CNS). Recent studies have shown that dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic diseases such as MS and may be potential targets for biomarkers and new therapeutic approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or therapeutic targets in MS.


Eligibility criteria: Inclusion Criteria:

* The age of 25 years and above
* at least one Central Nervous System (CNS) demyelination event

Exclusion Criteria:

* with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia, Sickle cell disease, iron deficiency, and B12 deficiency

Primary outcomes:
measure: miRNA expression
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06212895: Expectations of Patients Regarding Exercise in an Outpatient Clinic
Official title: Attitude and Expectations of Patients Regarding Exercise and Physical Activity as a Therapeutic Option in an Orthopedic Outpatient Clinic - A Cross-Sectional-Trial
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Communcation
Physical Activity
Prescription
Lead sponsor: University of Regensburg
Sponsor class: OTHER
Collaborators: name: OCS Straubing
First posted: 2024-01-19
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population includes patients, which present themself for the first time in this outpatient clinic.

Brief summary: Exercise and physical activity are recommended in many clinical guidelines in orthopdeci diseases. Costs, time, doctor-patient-communication and the type of prescription are possible limitations of prescribing exercise as a therapy. It is essential to know the expactiations and attitude of the patients for an accurate, patient-centered, prescription. This trial aims to reveal patients point of view and attitude.


Eligibility criteria: Inclusion Criteria:

* patient presented the first time in the outpatient study with an issue

Exclusion Criteria:

* language barrier
* cognitive impairment which could lead to missunderstadning of the survey

Primary outcomes:
measure: Attitude of patients regarding exercise and physical activity as a therapeutic option
timeFrame: July 2024
Secondary outcomes:
measure: influencing factors of patients attitude
timeFrame: July 2024
Other outcomes:
Locations:
city: Regensburg
country: Germany
facility: Department for Epidemiology and Preventive Medicine, Division of Medical Sociology, University of Regensburg
Study officials:
References:
Clinical trial NCT00803595: A Multinational Phase III Study of CS-8958 (MARVEL)
Official title: A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Influenza, Human
Keywords: Influenza
Neuraminidase inhibitor
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
First posted: 2008-12-05
Enrollment: 1002
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to confirm the efficacy of CS-8958 administered as a single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir phosphate using the time to alleviation of influenza illness. For safety evaluation, between-group comparisons will be made with regard to incidence of adverse events and other safety measures.

In a secondary objective, the optimum dosage of CS-8958 for this indication will be evaluated based on the efficacy and safety of single inhaled low or high dose.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of influenza
* Axillary temperature of \> or = to 37.5 degrees C

Exclusion Criteria:

* Infection by bacteria species and/or virus other than influenza virus
* Chronic respiratory disease
* Renal dysfunction

Primary outcomes:
measure: Time to Alleviation of Influenza Illness
timeFrame: 15 days
Secondary outcomes:
measure: Time for Body Temperature to Return to Normal
timeFrame: 15 days
Other outcomes:
Locations:
city: Hong-Kong
country: China
city: Tokyo
country: Japan
city: Seoul
country: Korea, Republic of
city: Taipei
country: Taiwan
Study officials:
References:
citation: Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010 Nov 15;51(10):1167-75. doi: 10.1086/656802. Epub 2010 Oct 11.
Clinical trial NCT03376295: Comparative Effectiveness of COPD Treatments
Official title: Comparative Effectiveness of Combination Therapies in COPD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Disease, Chronic Obstructive
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2017-12-18
Enrollment: 3954
Sex: ALL
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The base cohort will consist of all patients with a diagnosis of COPD from 1 January 1995 until 31 December 2015 who subsequently received at least one prescription for a long-acting bronchodilator, either LABA or tiotropium, or for an inhaled corticosteroid, alone or in combination, from 1 January 2002 until 31 December 2015.

Brief summary: To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium (LABA-TIO)) compared with the combination of a LABA and an ICS (LABA-ICS) on the time to COPD exacerbation.


Eligibility criteria: Inclusion Criteria:

* New users of long-acting bronchodilators, LABA and tiotropium on the same date or of LABA and ICS, either as a fixed-dose combination or free combination, on the same date between January 2002 and December 2015
* Diagnosis of COPD and age ≥ 55 years

Exclusion Criteria:

* Less than one year of medical history information prior to the date of combined treatment initiation (cohort entry)
* Asthma diagnosis

Primary outcomes:
measure: The Number of Observed Patients With First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation to Occur After Cohort Entry
timeFrame: 12 Years
Secondary outcomes:
measure: The Rate of COPD Exacerbations
timeFrame: 12 years
measure: The Occurrence of the First Hospitalization for Community-acquired Pneumonia (Serious Pneumonia)
timeFrame: 12 years
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Centre for Clinical Epidemiology, McGill University
Study officials:
References: